HistoSonics, the maker of the Edison® Histotripsy System, has successfully completed an oversubscribed $102 million Series D financing round. The funding was led by Alpha Wave Ventures, with participation from new investors like Amzak Health and HealthQuest Capital, as well as existing investors such as Johnson & Johnson Innovation and Venture Investors. This financial boost reflects strong confidence in HistoSonics’ innovative approach to treating tumors using focused ultrasound technology.
The company specializes in histotripsy, a groundbreaking form of focused ultrasound that uses short, high-amplitude pulses to create a “bubble cloud” designed to mechanically destroy and liquefy liver tumors. This technique offers a non-invasive and non-thermal method for tumor destruction, presenting a promising alternative to traditional treatments like surgery, radiation, and chemotherapy, which can have severe side effects. HistoSonics aims to provide patients with a more effective and less invasive option for tumor treatment.
The proceeds from the Series D funding will be directed towards advancing HistoSonics’ histotripsy platforms, supporting commercial growth in the U.S. and global markets, and launching the BOOMBOX Master Study. This study will evaluate the effectiveness of the Edison System in treating liver tumors across various medical disciplines. The Edison Histotripsy System received FDA De Novo clearance in October 2023, positioning the company to partner with leading institutions to develop multidisciplinary liver programs.
Mike Blue, the President & CEO of HistoSonics, expressed excitement about the investor support and the potential impact of histotripsy on patient care. The innovative technology aims to improve treatment outcomes while minimizing recovery times, offering a paradigm shift in tumor management. With strong backing and a commitment to pioneering new medical approaches, HistoSonics is set to redefine how tumors are treated and expand its applications to various other cancer types in the future.
Reference:
